amlodipine and Obesity studies

Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

Excerpt	Relevance	Reference
"Aliskiren penetrates adipose and skeletal muscle in hypertensive patients with abdominal obesity and reduces renin-angiotensin-aldosterone system activity."	9.24	Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension. ( Boschmann, M; Dahlke, M; Danser, AHJ; Dole, WP; Engeli, S; Jordan, J; May, M; Nussberger, J; Pal, P; Prescott, MF; Stitah, S, 2017)
"This prespecified subgroup analysis of a phase III study examined the effect of adding hydrochlorothiazide (HCTZ) to olmesartan (OLM)/amlodipine (AML) in patients with moderate to severe hypertension stratified by age, sex, body mass index, and hypertension severity."	9.19	Efficacy and tolerability of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: a subgroup analysis of patients stratified by hypertension severity, age, sex, and obesity. ( Ammentorp, B; de la Sierra, A; Kreutz, R; Laeis, P, 2014)
"After a 4-week placebo period, 58 overweight-obese (BMI >or=25 kg/m(2)) patients, with mild to moderate essential hypertension (DBP >95 and <110 mmHg, SBP >140 mmHg) were treated with amlodipine 5 mg od or valsartan 160 mg od or amlodipine 5 mg plus valsartan 160 mg od for 8 weeks according to a randomized, open-label, blinded end-point, cross-over study."	9.13	Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Santoro, T; Zoppi, A, 2008)
"The objective of this study was to assess the effect of amlodipine-atorvastatin combination on plasma interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and insulin sensitivity in normocholesterolemic obese hypertensive patients."	9.12	Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. ( Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A, 2006)
"To demonstrate that calcium channel blockers can improve insulin resistance clinically, we investigated the effects of the calcium channel blockers, amlodipine, manidipine and cilnidipine on serum levels of steroid hormones and insulin."	9.11	Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. ( Miyachi, Y; Ueshiba, H, 2004)
"We investigated the effects of the calcium channel blocker amlodipine besilate on serum levels of adrenal androgens and insulin in 20 men with essential hypertension and obesity (age: 51."	7.71	Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity. ( Miyachi, Y; Tsuboi, K; Ueshiba, H, 2001)
"To evaluate the effects of long-term treatment antihypertensive with the dihydropyridine calcium antagonist amlodipine on insulin sensitivity, plasma insulin, and lipoprotein metabolism in obese hypertensive patients."	7.68	Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. ( Böhlen, L; de Courten, M; Ferrari, P; Heynen, G; Riesen, W; Schneider, M; Shaw, S; Weidmann, P, 1993)
"Hypertension is particularly prevalent in patients aged ≥65 years, those with a body mass index ≥30 kg m(-2), Blacks and those with type II diabetes."	6.75	Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. ( Chrysant, SG; Heyrman, R; Karki, S; Lee, J; Melino, M, 2010)
"Aliskiren is a novel renin-angiotensin aldosterone system (RAAS) inhibitor, the combination therapy of aliskiren and amlodipine for blood pressure control have been reported recently."	6.49	Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials. ( Chen, K; Han, Y; Kou, X; Liu, Y; Zeng, C; Zhou, L, 2013)
"Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity."	5.36	Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010)
"Aliskiren penetrates adipose and skeletal muscle in hypertensive patients with abdominal obesity and reduces renin-angiotensin-aldosterone system activity."	5.24	Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension. ( Boschmann, M; Dahlke, M; Danser, AHJ; Dole, WP; Engeli, S; Jordan, J; May, M; Nussberger, J; Pal, P; Prescott, MF; Stitah, S, 2017)
" We prospectively examined randomization to first-step chlorthalidone, a thiazide-type diuretic; amlodipine, a calcium-channel blocker; and lisinopril, an angiotensin-converting enzyme inhibitor, on BP control and cardiovascular outcomes in a hypertensive cohort stratified by baseline BMI [kg/m(2); normal weight (BMI <25), overweight (BMI = 25-29."	5.19	Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. ( Barzilay, JI; Dart, RA; Davis, BR; Einhorn, PT; Graves, JW; Pressel, SL; Reisin, E; Retta, TM; Saklayen, MG; Yamal, JM, 2014)
"This prespecified subgroup analysis of a phase III study examined the effect of adding hydrochlorothiazide (HCTZ) to olmesartan (OLM)/amlodipine (AML) in patients with moderate to severe hypertension stratified by age, sex, body mass index, and hypertension severity."	5.19	Efficacy and tolerability of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: a subgroup analysis of patients stratified by hypertension severity, age, sex, and obesity. ( Ammentorp, B; de la Sierra, A; Kreutz, R; Laeis, P, 2014)
"This was a prospective trial of amlodipine 10 mg/day administered for 1 month in primary-care patients with hypertension (n = 28), 46% of whom were obese and 57% of whom displayed the metabolic syndrome."	5.15	Blood pressure-lowering response to amlodipine as a determinant of the antioxidative activity of small, dense HDL3. ( Bittar, R; Bonnefont-Rousselot, D; Bruckert, E; Chantepie, S; Chapman, MJ; Girerd, X; Hansel, B; Kontush, A; Orsoni, A, 2011)
"After a 4-week placebo period, 58 overweight-obese (BMI >or=25 kg/m(2)) patients, with mild to moderate essential hypertension (DBP >95 and <110 mmHg, SBP >140 mmHg) were treated with amlodipine 5 mg od or valsartan 160 mg od or amlodipine 5 mg plus valsartan 160 mg od for 8 weeks according to a randomized, open-label, blinded end-point, cross-over study."	5.13	Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Santoro, T; Zoppi, A, 2008)
"The objective of this study was to assess the effect of amlodipine-atorvastatin combination on plasma interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and insulin sensitivity in normocholesterolemic obese hypertensive patients."	5.12	Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. ( Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A, 2006)
"To demonstrate that calcium channel blockers can improve insulin resistance clinically, we investigated the effects of the calcium channel blockers, amlodipine, manidipine and cilnidipine on serum levels of steroid hormones and insulin."	5.11	Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. ( Miyachi, Y; Ueshiba, H, 2004)
"The primary objective of this study was to determine whether combination therapy with valsartan 160 mg plus hydrochlorothiazide (HCTZ) 25 mg OD would be more effective than monotherapy with amlodipine 10 mg OD in reducing systolic blood pressure (SBP) in patients with moderate (stage II) hypertension and > or =1 other cardiovascular risk factor or concomitant condition."	5.11	Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. ( Bönner, G; Heintz, D; Kandra, A; Khder, Y; Malacco, E; Ruilope, LM, 2005)
" This article considers the evidence supporting telmisartan/amlodipine combination therapy for the treatment of hypertension in patients with metabolic risk factors."	4.89	Telmisartan plus amlodipine single-pill combination for the management of hypertensive patients with a metabolic risk profile (added-risk patients). ( Ley, L; Schumacher, H, 2013)
"The CD feeding induced obesity, hyperphagia, hyperlipidaemia, and leptin and insulin resistance."	3.80	Chronic blockade of angiotensin AT₁ receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats. ( Barkhausen, J; Hübel, N; Mildner, M; Müller-Fielitz, H; Raasch, W; Vogt, FM, 2014)
" Metformin treatment improved the insulin sensitivity, and normalized the in vitro bladder hypercontractility and cystometric dysfunction in obese mice."	3.78	Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice. ( Anhê, GF; Antunes, E; Calixto, MC; De Nucci, G; Grant, AD; Leiria, LO; Lintomen, L; Mónica, FZ; Sollon, C; Zanesco, A, 2012)
"We investigated the effects of the calcium channel blocker amlodipine besilate on serum levels of adrenal androgens and insulin in 20 men with essential hypertension and obesity (age: 51."	3.71	Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity. ( Miyachi, Y; Tsuboi, K; Ueshiba, H, 2001)
" Each of five groups of obese hypertensives were treated with the long-acting calcium channel blocker (CCB) amlodipine, the angiotensin converting enzyme (ACE) inhibitor enalapril with or without a weight reduction program, or a weight reduction program alone."	3.71	Weight reduction and pharmacologic treatment in obese hypertensives. ( Masuo, K; Mikami, H; Ogihara, T; Tuck, ML, 2001)
"To evaluate the effects of long-term treatment antihypertensive with the dihydropyridine calcium antagonist amlodipine on insulin sensitivity, plasma insulin, and lipoprotein metabolism in obese hypertensive patients."	3.68	Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. ( Böhlen, L; de Courten, M; Ferrari, P; Heynen, G; Riesen, W; Schneider, M; Shaw, S; Weidmann, P, 1993)
"Hypertension and obesity are two major threats for public health."	2.80	The Effects of Valsartan and Amlodipine on the Levels of Irisin, Adropin, and Perilipin. ( Akkaya, N; Cakmak, M; Çelik, HT; Demircelik, B; Erdamar, H; Gok, S; Kazanci, F; Yigitoglu, R, 2015)
"Hypertension is particularly prevalent in patients aged ≥65 years, those with a body mass index ≥30 kg m(-2), Blacks and those with type II diabetes."	2.75	Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. ( Chrysant, SG; Heyrman, R; Karki, S; Lee, J; Melino, M, 2010)
"Amlodipine was used as the control drug."	2.72	Selective imidazoline agonist moxonidine in obese hypertensive patients. ( de Abreu, VG; Francischetti, EA; Sanjuliani, AF, 2006)
"Amlodipine treatment 1) lowered fasting serum insulin (from 273 +/- 19 to 200 +/- 17 pmol/L; P < 0."	2.67	The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men. ( Beer, NA; Beer, RM; Jakubowicz, DJ; Nestler, JE, 1993)
"Aliskiren is a novel renin-angiotensin aldosterone system (RAAS) inhibitor, the combination therapy of aliskiren and amlodipine for blood pressure control have been reported recently."	2.49	Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials. ( Chen, K; Han, Y; Kou, X; Liu, Y; Zeng, C; Zhou, L, 2013)
"Treatment with amlodipine, candesartan, or indapamide did not significantly affect plasma visfatin levels."	1.43	Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations. ( Piecha, G; Skoczylas, A; Więcek, A, 2016)
"Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity."	1.36	Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010)
"Non-alcoholic steatohepatitis (NASH), which is a common liver disease in industrialized countries, is associated with obesity, hypertension, and type-2 diabetes (metabolic syndrome)."	1.35	ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. ( Cao, G; Mastai, R; Mella, J; Muñoz, MC; Pereyra, L; Toblli, JE, 2008)
"Heart failure was two times more prevalent in obese patients."	1.34	[Overweight and obesity in hypertensive Spanish patients. The CORONARIA study]. ( Aguilar Llopis, A; Arístegui Urrestarazu, R; Armada Peláez, B; Cosín Aguilar, J; Hernándiz Martínez, A; Masramón Morell, X; Rodríguez Padial, L; Zamorano Gómez, JL, 2007)

Research

Studies (42)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

Change From Baseline in Postprandial Glucose

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (7.14)	18.2507
2000's	15 (35.71)	29.6817
2010's	23 (54.76)	24.3611
2020's	1 (2.38)	2.80

Authors	Studies
Chou, CL	1
Li, CH	1
Fang, TC	1
Engeli, S	4
May, M	2
Nussberger, J	2
Danser, AHJ	1
Dole, WP	1
Prescott, MF	2
Dahlke, M	2
Stitah, S	1
Pal, P	1
Boschmann, M	2
Jordan, J	4
Stinkens, R	1
van der Kolk, BW	1
Jax, T	1
Heise, T	1
Jocken, JW	1
Schindler, C	1
Havekes, B	1
Schaper, N	1
Albrecht, D	1
Kaiser, S	1
Hartmann, N	1
Letzkus, M	1
Langenickel, TH	1
Goossens, GH	1
Blaak, EE	1
Roth, EM	1
Oparil, S	1
Melino, M	2
Lee, J	2
Fernandez, V	1
Heyrman, R	2
Liu, Y	1
Chen, K	1
Kou, X	1
Han, Y	1
Zhou, L	1
Zeng, C	1
Sweiss, N	1
Sharma, K	1
Müller-Fielitz, H	1
Hübel, N	1
Mildner, M	1
Vogt, FM	1
Barkhausen, J	1
Raasch, W	1
Reisin, E	1
Graves, JW	1
Yamal, JM	1
Barzilay, JI	1
Pressel, SL	1
Einhorn, PT	1
Dart, RA	1
Retta, TM	1
Saklayen, MG	1
Davis, BR	1
Kreutz, R	1
Ammentorp, B	1
Laeis, P	1
de la Sierra, A	1
Olszanecka-Glinianowicz, M	1
Smertka, M	1
Almgren-Rachtan, A	1
Chudek, J	1
Çelik, HT	1
Akkaya, N	1
Erdamar, H	1
Gok, S	1
Kazanci, F	1
Demircelik, B	1
Cakmak, M	1
Yigitoglu, R	1
Skoczylas, A	1
Piecha, G	1
Więcek, A	1
Fogari, R	2
Preti, P	2
Zoppi, A	2
Mugellini, A	1
Corradi, L	2
Lazzari, P	2
Santoro, T	1
Derosa, G	2
Chrysant, SG	1
Karki, S	1
Nakao, K	1
Hirata, M	1
Oba, K	1
Yasuno, S	1
Ueshima, K	1
Fujimoto, A	1
Ogihara, T	2
Saruta, T	1
Sowers, JR	2
Raij, L	2
Jialal, I	1
Egan, BM	2
Ofili, EO	1
Samuel, R	2
Zappe, DH	2
Purkayastha, D	2
Deedwania, PC	1
Punzi, H	1
Shojaee, A	2
Waverczak, WF	1
Maa, JF	2
Hansel, B	1
Girerd, X	1
Bonnefont-Rousselot, D	1
Bittar, R	1
Chantepie, S	1
Orsoni, A	1
Bruckert, E	1
Chapman, MJ	1
Kontush, A	1
Danser, AH	1
Yeh, CM	1
Hsueh, WA	1
Neutel, JM	1
Leiria, LO	1
Sollon, C	1
Calixto, MC	1
Lintomen, L	1
Mónica, FZ	1
Anhê, GF	1
De Nucci, G	1
Zanesco, A	1
Grant, AD	1
Antunes, E	1
Ley, L	1
Schumacher, H	1
Weber, MA	1
Jamerson, K	1
Bakris, GL	1
Weir, MR	1
Zappe, D	1
Zhang, Y	1
Dahlof, B	1
Velazquez, EJ	1
Pitt, B	1
Takagi, H	1
Mizuno, Y	1
Yamamoto, H	1
Goto, SN	1
Umemoto, T	1
Ueshiba, H	2
Miyachi, Y	2
Ersoy, C	1
Imamoğlu, S	1
Budak, F	1
Tuncel, E	1
Ertürk, E	1
Oral, B	1
Ruilope, LM	1
Malacco, E	1
Khder, Y	1
Kandra, A	1
Bönner, G	1
Heintz, D	1
Sanjuliani, AF	1
de Abreu, VG	1
Francischetti, EA	1
Fogari, E	1
Ciccarelli, L	1
Boye, SW	1
Le Breton, S	1
Keefe, DL	1
Mori, Y	1
Itoh, Y	1
Tajima, N	1
Cosín Aguilar, J	1
Hernándiz Martínez, A	1
Masramón Morell, X	1
Arístegui Urrestarazu, R	1
Aguilar Llopis, A	1
Zamorano Gómez, JL	1
Armada Peláez, B	1
Rodríguez Padial, L	1
Kagota, S	1
Tada, Y	1
Kubota, Y	1
Nejime, N	1
Yamaguchi, Y	1
Nakamura, K	1
Kunitomo, M	1
Shinozuka, K	1
Toblli, JE	1
Muñoz, MC	1
Cao, G	1
Mella, J	1
Pereyra, L	1
Mastai, R	1
Rosa, EC	1
Zanella, MT	1
Kohlmann, NE	1
Ferreira, SR	1
Plavnik, FL	1
Ribeiro, AB	1
Kohlmann, O	1
Ruvolo, G	1
Greco, E	1
Speziale, G	1
Di Natale, M	1
Marino, B	1
de Courten, M	1
Ferrari, P	1
Schneider, M	1
Böhlen, L	1
Shaw, S	1
Riesen, W	1
Heynen, G	1
Weidmann, P	1
Beer, NA	1
Jakubowicz, DJ	1
Beer, RM	1
Nestler, JE	1
Tsuboi, K	1
Masuo, K	1
Mikami, H	1
Tuck, ML	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
[NCT00000542]	Phase 3	0 participants	Interventional	1993-08-31	Completed
A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients[NCT00439738]	Phase 4	412 participants (Actual)	Interventional	2006-12-31	Completed
A 10-week Multicenter,Forced-titration Study Using 24-hr ABPM to Evaluate the Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Treatment Regimen vs Conventional Treatment Regimen With Amlodipine and Hydrochlorothiazide (HCTZ) in Patients With Stage 2 Hype[NCT00425997]	Phase 4	480 participants (Anticipated)	Interventional	2006-12-31	Completed
A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety Safety of AZOR in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy[NCT00791258]	Phase 4	999 participants (Actual)	Interventional	2008-11-30	Completed
A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension[NCT00170950]	Phase 3	11,506 participants (Actual)	Interventional	2003-10-31	Terminated (stopped due to The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.)
A 12-week Randomized Double-blind Parallel Group Study to Evaluate the Efficacy and Safety of the Combination Aliskiren With HCTZ Compared to Irbesartan or Amlodipine With HCTZ or HCTZ Alone in Hypertensive Patients With BMI ≥ 30 kg/m2 Not Adequately Resp[NCT00219115]	Phase 3	493 participants (Actual)	Interventional	2005-01-31	Completed
Treatment of Essential Hypertension With Rasilez. Evaluation of Different Methods of Blood Pressure Measurements - Efficacy and Safety Evaluation[NCT01060865]	Phase 4	50 participants (Actual)	Interventional	2010-03-31	Terminated (stopped due to The participants signed an old version of the informed consent.)
Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension[NCT01444833]		35 participants (Anticipated)	Interventional	2008-10-31	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16

Change From Baseline in Postprandial Insulin

Intervention	mg/dL (Mean)
	Baseline visit (0 minutes)	Week 16 (0 minutes)	Change from baseline to week 16 (0 minutes)	Baseline visit (120 minutes)	Week 16 (120 minutes)	Change from baseline to week 16 (120 minutes)
HCTZ +Amlodipine	99.4	102.8	3.4	127.7	146.5	18.9
Valsartan/HCTZ (Hydrochlorothiazide)	98.0	98.1	-0.5	123.9	126.3	2.1

After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16

Change From Baseline in Postprandial Non-esterified Fatty Acids

Intervention	mg/dL (Mean)
	Baseline visit (0 minutes)	Week 16 (0 minutes)	Change from baseline to week 16 (0 minutes)	Baseline visit (120 minutes)	Week 16 (120 minutes)	Change from baseline to week 16 (120 minute)
HCTZ +Amlodipine	20.37	23.62	3.67	95.95	120.01	28.07
Valsartan/HCTZ (Hydrochlorothiazide)	19.66	23.45	3.41	92.04	116.04	24.68

After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16

Change in Mean Sitting Diastolic Blood Pressure (MSDBP)

Change in Mean Sitting Systolic Blood Pressure (MSSBP)

Number of Patients Achieving Blood Pressure (BP) Control by Visit (< 140/90 mm Hg)

Intervention	mg/dL (Mean)
	Baseline visit (0 minutes)	Week 16 (0 minutes)	Change from baseline to week 16 (0 minutes)	Baseline visit (120 minutes)	Week 16 (120 minutes)	Change from baseline to week 16 (120 minutes)
HCTZ +Amlodipine	0.47	0.47	0.00	0.10	0.10	-0.01
Valsartan/HCTZ (Hydrochlorothiazide)	0.45	0.46	0.01	0.11	0.10	-0.01

Intervention	mm Hg (Mean)
	Baseline	Week 4	Week 8	Week 12	Week 16	Change from baseline to week 16
HCTZ +Amlodipine	93.6	87.6	85.1	82.8	80.9	-12.7
Valsartan/HCTZ (Hydrochlorothiazide)	94.9	85.7	81.9	81.1	80.8	-14.0

Intervention	mm Hg (Mean)
	Baseline	Week 8	Change from baseline
HCTZ +Amlodipine	159.0	137.5	-21.5
Valsartan/HCTZ (Hydrochlorothiazide)	159.7	131.2	-28.6

Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 140/90 mm Hg (NCT00439738)
Timeframe: Weeks 4, 8, 12 16 and End of Study (for patients that did not complete the last visit at week 16)

Number of Patients Achieving Blood Pressure (BP)Control by Visit (< 130/80 mm Hg)

Intervention	participants (Number)
	Week 4	Week 8	Week 12	Week 16	End of study
HCTZ +Amlodipine	69	102	112	140	146
Valsartan/HCTZ (Hydrochlorothiazide)	91	123	122	124	133

Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 130/80 mm Hg (NCT00439738)
Timeframe: Week 4, 8, 12, 16, End of Study (for patients that did not complete the last visit at week 16)

The Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (<140 mm Hg for Non-diabetics and <130 mm Hg for Diabetics) From Baseline to 12 Weeks

The Percentage of Subjects Achieving Seated Diastolic BP Goal (<90 mmHg for Non-diabetics or < 80 mmHg for Subjects With Diabetes) From Baseline to 12 Weeks

Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values

Intervention	participants (Number)
	Week 4	Week 8	Week 12	Week 16	End of Study
HCTZ +Amlodipine	18	23	46	65	68
Valsartan/HCTZ (Hydrochlorothiazide)	33	59	57	62	68

Intervention	Percentage of participants (Number)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	75.8

Intervention	Percentage of participants (Number)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	84.3

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8 a.m. to 4 p.m. Nighttime is defined as 10 p.m. to 6 a.m. (NCT00791258)
Timeframe: Baseline to 12 weeks

Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values

Intervention	mm Hg (Mean)
	24-hour mean systolic blood pressure	Mean daytime systolic blood pressure	Mean nighttime systolic blood pressure	Systolic blood pressure - last 2 hours of dose	Systolic blood pressure - last 4 hours of dose	Systolic blood pressure - last 6 hours of dose	24-hour mean diastolic blood pressure	Mean daytime diastolic blood pressure	Mean nighttime diastolic blood pressure	Diastolic blood pressure - last 2 hours of dose	Diastolic blood pressure - last 4 hours of dose	Diastolic blood pressure - last 6 hours of dose
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	-14.8	-16.3	-12.5	-13.6	-13.0	-12.6	-9.4	-10.6	-7.6	-8.6	-8.0	-7.7

Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks

Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Intervention	mm Hg (Mean)
	24-hour mean systolic blood pressure	Mean daytime systolic blood pressure	Mean nighttime systolic blood pressure	Systolic blood pressure - last 2 hours of dose	Systolic blood pressure - last 4 hours of dose	Systolic blood pressure - last 6 hours of dose	24-hour mean diastolic blood pressure	Mean daytime diastolic blood pressure	Mean nighttime diastolic blood pressure	Diastolic blood pressure - last 2 hours of dose	Diastolic blood pressure - last 4 hours of dose	Diastolic blood pressure - last 6 hours of dose
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	-21.0	-23.2	-17.5	-19.6	-18.2	-17.9	-13.3	-15.0	-11.1	-12.3	-11.6	-11.3

Intervention	mm Hg (Mean)
	4 weeks, N=975	8 weeks, N=929	12 weeks, N=865	16 weeks, N=797	20 weeks, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	-8.1	-9.1	-11.9	-14.6	-14.5

Intervention	mm Hg (Mean)
	4 weeks, N=975	8 weeks, N=929	12 weeks, N=865	16 weeks, N=797	20 weeks, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	-14.6	-16.6	-21.8	-26.0	-26.8

Intervention	Percentage of Participants (Number)
	4 weeks: <140/90 mm Hg, N=230	4 weeks: <135/80 mm Hg, N=230	4 weeks: <130/80 mm Hg, N=230	4 weeks: <120/80 mm Hg, N=230	8 weeks: <140/90 mm Hg, N=231	8 weeks: <135/80 mm Hg, N=231	8 weeks: <130/80 mm Hg, N=232	8 weeks: <120/80 mm Hg, N=232	12 weeks: <140/90mm Hg, N=232	12 weeks: <135/80 mm Hg, N=232	12 weeks: <130/80 mm Hg, N=232	12 weeks: <120/80 mm Hg, N=232	16 weeks: <140/90 mm Hg, N=232	16 weeks: <135/80 mm Hg, N=232	16 weeks: <130/80 mm Hg, N=232	16 weeks: <120/80 mm Hg, N=232	20 weeks: <140/90 mm Hg, N=232	20 weeks: <135/80 mm Hg, N=232	20 weeks: <130/80 mm Hg, N=232	20 weeks: <120/80 mm Hg, N=232
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	45.7	14.8	10.4	3.9	55.0	23.8	20.8	10.4	68.5	38.4	35.8	16.4	80.6	49.1	47.4	30.6	86.6	57.8	55.2	39.7

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=230	4 weeks: <85 mm Hg, N=230	4 weeks: <80 mm Hg, N=230	8 weeks: <90 mm Hg, N=231	8 weeks: <85 mm Hg, N=231	8 weeks: <80 mm Hg, N=231	12 weeks: <90 mm Hg, N=232	12 weeks: <85 mm Hg, N=232	12 weeks: <80 mm Hg, N=232	16 weeks: <90 mm Hg, N=232	16 weeks: <85 mm Hg, N=232	16 weeks: <80 mm Hg, N=232	20 weeks: <90 mm Hg, N=232	20 weeks: <85 mm Hg, N=232	20 weeks: <80 mm Hg, N=232
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	60.9	42.2	19.6	71.9	53.7	30.3	82.3	66.0	45.3	92.2	76.3	55.2	94.8	80.6	61.2

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=230	4 weeks: >10 and ≤ 15 mm Hg, N=230	4 weeks: >15 and ≤ 20 mm Hg, N=230	4 weeks: >20 mm Hg, N=230	8 weeks: ≤ 10 mm Hg, N=220	8 weeks: >10 and ≤ 15 mm Hg, N=220	8 weeks: >15 and ≤ 20 mm Hg, N=220	8 weeks: >20 mm Hg, N=220	12 weeks: ≤ 10 mm Hg, N=208	12 weeks: >10 and ≤15 mm Hg, N=208	12 weeks: >15 and ≤ 20 mm Hg, N=208	12 weeks: >20 mm Hg, N=208	16 weeks: ≤ 10 mm Hg, N=199	16 weeks: >10 and ≤ 15 mm Hg, N=199	16 weeks: >15 and ≤ 20 mm Hg, N=199	16 weeks: >20 mm Hg, N=199	20 weeks: ≤ 10 mm Hg, N=189	20 weeks: >10 and ≤ 15 mm Hg, N=189	20 weeks: >15 and ≤ 20 mm Hg, N=189	20 weeks: >20 mm Hg, N=189
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	70.0	17.8	7.9	4.4	66.8	15.0	10.9	7.3	54.8	21.2	12.0	12.0	38.7	19.6	23.1	18.6	36.0	19.6	20.6	23.8

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=230	4 weeks: <135 mm Hg, N=230	4 weeks: <130 mm Hg, N=230	4 weeks: <120 mm Hg, N=230	8 weeks: <140 mm Hg, N=231	8 weeks: <135 mm Hg, N=231	8 weeks: <130 mm Hg, N=231	8 weeks: <120 mm Hg, N=231	12 weeks: <140 mm Hg, N=232	12 weeks: <135 mm Hg, N=232	12 weeks: <130 mm Hg, N=232	12 weeks: <120 mm Hg, N=232	16 weeks: <140 mm Hg, N=232	16 weeks: <135 mm Hg, N=232	16 weeks: <130 mm Hg, N=232	16 weeks: <120 mm Hg, N=232	20 weeks: <140 mm Hg, N=232	20 weeks: <135 mm Hg, N=232	20 weeks: <130 mm Hg, N=232	20 weeks: <120 mm Hg, N=232
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	51.7	34.4	19.6	5.7	62.3	44.6	33.8	13.0	76.3	59.1	47.0	19.8	84.9	71.1	61.2	34.1	91.0	80.6	71.1	44.4

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=230	4 weeks: >15 and ≤ 30 mm Hg, N=230	4 weeks: >30 and ≤ 45 mm Hg, N=230	4 weeks: >45 mm Hg, N=230	8 weeks: ≤ 15 mm Hg, N=220	8 weeks: >15 and ≤ 30 mm Hg, N=220	8 weeks: >30 and ≤ 45 mm Hg, N=220	8 weeks: >45 mm Hg, N=220	12 weeks: ≤ 15 mm Hg, N=208	12 weeks: >15 and ≤ 30 mm Hg, N=208	12 weeks: >30 and ≤ 45 mm Hg, N=208	12 weeks: >45 mm Hg, N=208	16 weeks: ≤ 15 mm Hg, N=199	16 weeks: >15 and ≤ 30 mm Hg, N=199	16 weeks: >30 and ≤ 45 mm Hg, N=199	16 weeks: >45 mm Hg, N=199	20 weeks: ≤ 15 mm Hg, N=189	20 weeks: >15 and ≤ 30 mm Hg, N=189	20 weeks: >30 and ≤ 45 mm Hg, N=189	20 weeks: >45 mm Hg, N=189
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	60.0	32.2	7.4	0.4	53.6	38.2	7.3	0.9	38.9	41.8	16.4	2.9	30.7	37.2	25.1	7.0	24.3	37.6	29.6	8.5

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=128	4 weeks: <85 mm Hg, N=128	4 weeks: <80 mm Hg, N=128	8 weeks: <90 mm Hg, N=128	8 weeks: <85 mm Hg, N=128	8 weeks: <80 mm Hg, N=128	12 weeks: <90 mm Hg, N=128	12 weeks: <85 mm Hg, N=128	12 weeks: <80 mm Hg, N=128	16 weeks: <90 mm Hg, N=128	16 weeks: <85 mm Hg, N=128	16 weeks: <80 mm Hg, N=128	20 weeks: <90 mm Hg, N=128	20 weeks: <85 mm Hg, N=128	20 weeks: <80 mm Hg, N=128
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	83.6	69.5	45.3	89.1	79.7	60.2	95.3	87.5	71.1	96.9	93.0	82.0	96.9	93.0	85.2

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=126	4 weeks: >10 and ≤ 15 mm Hg, N=126	4 weeks: >15 and ≤ 20 mm Hg, N=126	4 weeks: >20 mm Hg, N=126	8 weeks: ≤ 10 mm Hg, N=123	8 weeks: >10 and ≤ 15 mm Hg, N=123	8 weeks: >15 and ≤ 20 mm Hg, N=123	8 weeks: >20 mm Hg, N=123	12 weeks: ≤ 10 mm Hg, N=120	12 weeks: >10 and ≤15 mm Hg, N=120	12 weeks: >15 and ≤ 20 mm Hg, N=120	12 weeks: >20 mm Hg, N=120	16 weeks: ≤ 10 mm Hg, N=112	16 weeks: >10 and ≤ 15 mm Hg, N=112	16 weeks: >15 and ≤ 20 mm Hg, N=112	16 weeks: >20 mm Hg, N=112	20 weeks: ≤ 10 mm Hg, N=105	20 weeks: >10 and ≤ 15 mm Hg, N=105	20 weeks: >15 and ≤ 20 mm Hg, N=105	20 weeks: >20 mm Hg, N=105
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	47.6	26.2	13.5	12.7	38.2	24.4	22.0	15.5	33.3	25.8	19.2	21.7	27.7	17.0	20.5	34.8	36.2	16.2	18.1	29.5

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=128	4 weeks: <135 mm Hg, N=128	4 weeks: <130 mm Hg, N=128	4 weeks: <120 mm Hg, N=128	8 weeks: <140 mm Hg, N=128	8 weeks: <135 mm Hg, N=128	8 weeks: <130 mm Hg, N=128	8 weeks: <120 mm Hg, N=128	12 weeks: <140 mm Hg, N=128	12 weeks: <135 mm Hg, N=128	12 weeks: <130 mm Hg, N=128	12 weeks: <120 mm Hg, N=128	16 weeks: <140 mm Hg, N=128	16 weeks: <135 mm Hg, N=128	16 weeks: <130 mm Hg, N=128	16 weeks: <120 mm Hg, N=128	20 weeks: <140 mm Hg, N=128	20 weeks: <135 mm Hg, N=128	20 weeks: <130 mm Hg, N=128	20 weeks: <120 mm Hg, N=128
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	64.8	51.6	35.2	11.7	76.6	67.2	51.6	25.0	89.1	78.9	66.4	38.3	95.3	89.8	81.3	47.7	97.7	93.0	85.9	51.6

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=126	4 weeks: >15 and ≤ 30 mm Hg, N=126	4 weeks: >30 and ≤ 45 mm Hg, N=126	4 weeks: >45 mm Hg, N=126	8 weeks: ≤ 15 mm Hg, N=123	8 weeks: >15 and ≤ 30 mm Hg, N=123	8 weeks: >30 and ≤ 45 mm Hg, N=123	8 weeks: >45 mm Hg, N=123	12 weeks: ≤ 15 mm Hg, N=120	12 weeks: >15 and ≤ 30 mm Hg, N=120	12 weeks: >30 and ≤ 45 mm Hg, N=120	12 weeks: >45 mm Hg, N=120	16 weeks: ≤ 15 mm Hg, N=112	16 weeks: >15 and ≤ 30 mm Hg, N=112	16 weeks: >30 and ≤ 45 mm Hg, N=112	16 weeks: >45 mm Hg, N=112	20 weeks: ≤ 15 mm Hg, N=105	20 weeks: >15 and ≤ 30 mm Hg, N=105	20 weeks: >30 and ≤ 45 mm Hg, N=105	20 weeks: >45 mm Hg, N=105
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	43.7	38.1	15.9	2.4	40.7	35.8	22.0	1.6	28.3	39.2	27.5	5.0	20.5	36.6	31.3	11.6	29.5	28.6	33.3	8.6

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=227	4 weeks: <85 mm Hg, N=227	4 weeks: <80 mm Hg, N=227	8 weeks: <90 mm Hg, N=227	8 weeks: <85 mm Hg, N=227	8 weeks: <80 mm Hg, N=227	12 weeks: <90 mm Hg, N=227	12 weeks: <85 mm Hg, N=227	12 weeks: <80 mm Hg, N=227	16 weeks: <90 mm Hg, N=227	16 weeks: <85 mm Hg, N=227	16 weeks: <80 mm Hg, N=227	20 weeks: <90 mm Hg, N=227	20 weeks: <85 mm Hg, N=227	20 weeks: <80 mm Hg, N=227
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	88.1	76.7	58.2	92.1	83.7	71.8	97.4	92.1	80.2	98.7	94.3	88.6	98.7	95.2	90.3

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=224	4 weeks: >10 and ≤ 15 mm Hg, N=224	4 weeks: >15 and ≤ 20 mm Hg, N=224	4 weeks: >20 mm Hg, N=224	8 weeks: ≤ 10 mm Hg, N=217	8 weeks: >10 and ≤ 15 mm Hg, N=217	8 weeks: >15 and ≤ 20 mm Hg, N=217	8 weeks: >20 mm Hg, N=217	12 weeks: ≤ 10 mm Hg, N=199	12 weeks: >10 and ≤15 mm Hg, N=199	12 weeks: >15 and ≤ 20 mm Hg, N=199	12 weeks: >20 mm Hg, N=199	16 weeks: ≤ 10 mm Hg, N=179	16 weeks: >10 and ≤ 15 mm Hg, N=179	16 weeks: >15 and ≤ 20 mm Hg, N=179	16 weeks: >20 mm Hg, N=179	20 weeks: ≤ 10 mm Hg, N=166	20 weeks: >10 and ≤ 15 mm Hg, N=166	20 weeks: >15 and ≤ 20 mm Hg, N=166	20 weeks: >20 mm Hg, N=166
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	63.8	20.5	9.4	6.3	57.1	19.8	14.3	8.8	45.2	25.1	15.6	14.1	27.4	25.1	22.9	24.6	34.9	20.5	24.1	20.5

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=227	4 weeks: <135 mm Hg, N=227	4 weeks: <130 mm Hg, N=227	4 weeks: <120 mm Hg, N=227	8 weeks: <140 mm Hg, N=227	8 weeks: <135 mm Hg, N=227	8 weeks: <130 mm Hg, N=227	8 weeks: <120 mm Hg, N=227	12 weeks: <140 mm Hg, N=227	12 weeks: <135 mm Hg, N=227	12 weeks: <130 mm Hg, N=227	12 weeks: <120 mm Hg, N=227	16 weeks: <140 mm Hg, N=227	16 weeks: <135 mm Hg, N=227	16 weeks: <130 mm Hg, N=227	16 weeks: <120 mm Hg, N=227	20 weeks: <140 mm Hg, N=227	20 weeks: <135 mm Hg, N=227	20 weeks: <130 mm Hg, N=227	20 weeks: <120 mm Hg, N=227
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	52.0	37.9	23.4	9.7	67.0	57.7	43.6	18.1	80.6	70.0	56.8	28.6	87.7	79.7	70.9	43.6	91.6	85.9	78.9	50.7

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=224	4 weeks: >15 and ≤ 30 mm Hg, N=224	4 weeks: >30 and ≤ 45 mm Hg, N=224	4 weeks: >45 mm Hg, N=224	8 weeks: ≤ 15 mm Hg, N=217	8 weeks: >15 and ≤ 30 mm Hg, N=217	8 weeks: >30 and ≤ 45 mm Hg, N=217	8 weeks: >45 mm Hg, N=217	12 weeks: ≤ 15 mm Hg, N=199	12 weeks: >15 and ≤ 30 mm Hg, N=199	12 weeks: >30 and ≤ 45 mm Hg, N=199	12 weeks: >45 mm Hg, N=199	16 weeks: ≤ 15 mm Hg, N=179	16 weeks: >15 and ≤ 30 mm Hg, N=179	16 weeks: >30 and ≤ 45 mm Hg, N=179	16 weeks: >45 mm Hg, N=179	20 weeks: ≤ 15 mm Hg, N=166	20 weeks: >15 and ≤ 30 mm Hg, N=166	20 weeks: >30 and ≤ 45 mm Hg, N=166	20 weeks: >45 mm Hg, N=166
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	47.3	40.2	11.2	1.3	42.9	37.8	16.6	2.8	26.6	46.7	24.6	2.0	17.9	32.4	39.7	10.1	14.5	37.4	38.0	10.2

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=98	4 weeks: <85 mm Hg, N=98	4 weeks: <80 mm Hg, N=98	8 weeks: <90 mm Hg, N=100	8 weeks: <85 mm Hg, N=100	8 weeks: <80 mm Hg, N=100	12 weeks: <90 mm Hg, N=100	12 weeks: <85 mm Hg, N=100	12 weeks: <80 mm Hg, N=100	16 weeks: <90 mm Hg, N=100	16 weeks: <85 mm Hg, N=100	16 weeks: <80 mm Hg, N=100	20 weeks: <90 mm Hg, N=100	20 weeks: <85 mm Hg, N=100	20 weeks: <80 mm Hg, N=100
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	66.3	53.1	34.7	85.0	70.0	48.0	92.0	78.0	62.0	96.0	90.0	75.0	96.0	90.0	75.0

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=98	4 weeks: >10 and ≤ 15 mm Hg, N=98	4 weeks: >15 and ≤ 20 mm Hg, N=98	4 weeks: >20 mm Hg, N=98	8 weeks: ≤ 10 mm Hg, N=91	8 weeks: >10 and ≤ 15 mm Hg, N=91	8 weeks: >15 and ≤ 20 mm Hg, N=91	8 weeks: >20 mm Hg, N=91	12 weeks: ≤ 10 mm Hg, N=83	12 weeks: >10 and ≤15 mm Hg, N=83	12 weeks: >15 and ≤ 20 mm Hg, N=83	12 weeks: >20 mm Hg, N=83	16 weeks: ≤ 10 mm Hg, N=75	16 weeks: >10 and ≤ 15 mm Hg, N=75	16 weeks: >15 and ≤ 20 mm Hg, N=75	16 weeks: >20 mm Hg, N=75	20 weeks: ≤ 10 mm Hg, N=71	20 weeks: >10 and ≤ 15 mm Hg, N=71	20 weeks: >15 and ≤ 20 mm Hg, N=71	20 weeks: >20 mm Hg, N=71
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	65.3	16.3	8.2	10.2	52.8	18.7	14.3	14.3	41.0	20.5	14.5	24.1	30.7	25.3	16.0	28.0	31.0	12.7	26.8	29.6

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=98	4 weeks: <135 mm Hg, N=98	4 weeks: <130 mm Hg, N=98	4 weeks: <120 mm Hg, N=98	8 weeks: <140 mm Hg, N=100	8 weeks: <135 mm Hg, N=100	8 weeks: <130 mm Hg, N=100	8 weeks: <120 mm Hg, N=100	12 weeks: <140 mm Hg, N=100	12 weeks: <135 mm Hg, N=100	12 weeks: <130 mm Hg, N=100	12 weeks: <120 mm Hg, N=100	16 weeks: <140 mm Hg, N=100	16 weeks: <135 mm Hg, N=100	16 weeks: <130 mm Hg, N=100	16 weeks: <120 mm Hg, N=100	20 weeks: <140 mm Hg, N=100	20 weeks: <135 mm Hg, N=100	20 weeks: <130 mm Hg, N=100	20 weeks: <120 mm Hg, N=100
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	55.1	39.8	31.6	10.2	64.0	51.0	41.0	15.0	77.0	67.0	54.0	30.0	84.0	77.0	66.0	37.0	88.0	83.0	72.0	41.0

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=98	4 weeks: >15 and ≤ 30 mm Hg, N=98	4 weeks: >30 and ≤ 45 mm Hg, N=98	4 weeks: >45 mm Hg, N=98	8 weeks: ≤ 15 mm Hg, N=91	8 weeks: >15 and ≤ 30 mm Hg, N=91	8 weeks: >30 and ≤ 45 mm Hg, N=91	8 weeks: >45 mm Hg, N=91	12 weeks: ≤ 15 mm Hg, N=83	12 weeks: >15 and ≤ 30 mm Hg, N=83	12 weeks: >30 and ≤ 45 mm Hg, N=83	12 weeks: >45 mm Hg, N=83	16 weeks: ≤ 15 mm Hg, N=75	16 weeks: >15 and ≤ 30 mm Hg, N=75	16 weeks: >30 and ≤ 45 mm Hg, N=75	16 weeks: >45 mm Hg, N=75	20 weeks: ≤ 15 mm Hg, N=71	20 weeks: >15 and ≤ 30 mm Hg, N=71	20 weeks: >30 and ≤ 45 mm Hg, N=71	20 weeks: >45 mm Hg, N=71
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	50.0	37.8	7.1	5.1	42.9	44.0	9.9	3.3	31.3	36.1	25.3	7.2	22.7	36.0	34.7	6.7	23.9	33.8	33.8	8.5

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=497	4 weeks: <85 mm Hg, N=497	4 weeks: <80 mm Hg, N=497	8 weeks: <90 mm Hg, N=497	8 weeks: <85 mm Hg, N=500	8 weeks: <80 mm Hg, N=500	12 weeks: <90 mm Hg, N=500	12 weeks: <85 mm Hg, N=500	12 weeks: <80 mm Hg, N=500	16 weeks: <90 mm Hg, N=500	16 weeks: <85 mm Hg, N=500	16 weeks: <80 mm Hg, N=500	20 weeks: <90 mm Hg, N=500	20 weeks: <85 mm Hg, N=500	20 weeks: <80 mm Hg, N=500
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	63.2	46.3	26.0	77.2	59.4	38.8	86.6	69.8	48.4	93.2	80.4	60.4	94.6	83.8	67.6

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=495	4 weeks: >10 and ≤ 15 mm Hg, N=495	4 weeks: >15 and ≤ 20 mm Hg, N=495	4 weeks: >20 mm Hg, N=495	8 weeks: ≤ 10 mm Hg, N=468	8 weeks: >10 and ≤ 15 mm Hg, N=468	8 weeks: >15 and ≤ 20 mm Hg, N=468	8 weeks: >20 mm Hg, N=468	12 weeks: ≤ 10 mm Hg, N=436	12 weeks: >10 and ≤15 mm Hg, N=436	12 weeks: >15 and ≤ 20 mm Hg, N=436	12 weeks: >20 mm Hg, N=436	16 weeks: ≤ 10 mm Hg, N=400	16 weeks: >10 and ≤ 15 mm Hg, N=400	16 weeks: >15 and ≤ 20 mm Hg, N=400	16 weeks: >20 mm Hg, N=400	20 weeks: ≤ 10 mm Hg, N=379	20 weeks: >10 and ≤ 15 mm Hg, N=379	20 weeks: >15 and ≤ 20 mm Hg, N=379	20 weeks: >20 mm Hg, N=379
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	67.5	17.8	8.5	6.3	59.4	19.9	13.0	7.7	48.9	22.5	16.1	12.6	33.3	23.0	19.0	24.8	31.9	18.7	22.4	26.9

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=497	4 weeks: <135 mm Hg, N=497	4 weeks: <130 mm Hg, N=497	4 weeks: <120 mm Hg, N=497	8 weeks: <140 mm Hg, N=500	8 weeks: <135 mm Hg, N=500	8 weeks: <130 mm Hg, N=500	8 weeks: <120 mm Hg, N=500	12 weeks: <140 mm Hg, N=500	12 weeks: <135 mm Hg, N=500	12 weeks: <130 mm Hg, N=500	12 weeks: <120 mm Hg, N=500	16 weeks: <140 mm Hg, N=500	16 weeks: <135 mm Hg, N=500	16 weeks: <130 mm Hg, N=500	16 weeks: <120 mm Hg, N=500	20 weeks: <140 mm Hg, N=500	20 weeks: <135 mm Hg, N=500	20 weeks: <130 mm Hg, N=500	20 weeks: <120 mm Hg, N=500
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	51.3	37.2	23.3	7.9	63.2	49.2	37.0	13.8	76.6	61.6	49.2	23.2	85.8	75.6	63.6	34.6	90.2	82.6	72.2	43.0

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=495	4 weeks: >15 and ≤ 30 mm Hg, N=495	4 weeks: >30 and ≤ 45 mm Hg, N=495	4 weeks: >45 mm Hg, N=495	8 weeks: ≤ 15 mm Hg, N=468	8 weeks: >15 and ≤ 30 mm Hg, N=468	8 weeks: >30 and ≤ 45 mm Hg, N=468	8 weeks: >45 mm Hg, N=468	12 weeks: ≤ 15 mm Hg, N=436	12 weeks: >15 and ≤ 30 mm Hg, N=436	12 weeks: >30 and ≤ 45 mm Hg, N=436	12 weeks: >45 mm Hg, N=436	16 weeks: ≤ 15 mm Hg, N=400	16 weeks: >15 and ≤ 30 mm Hg, N=400	16 weeks: >30 and ≤ 45 mm Hg, N=400	16 weeks: >45 mm Hg, N=400	20 weeks: ≤ 15 mm Hg, N=379	20 weeks: >15 and ≤ 30 mm Hg, N=379	20 weeks: >30 and ≤ 45 mm Hg, N=379	20 weeks: >45 mm Hg, N=379
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	56.0	35.2	8.5	0.4	52.4	35.9	10.3	1.5	37.8	42.4	17.4	2.5	27.8	36.0	27.5	8.8	20.6	37.5	33.3	8.7

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. (NCT00791258)
Timeframe: Baseline to 12 weeks

Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Intervention	Percentage of participants (Number)
	24-hour mean systolic blood pressure <140 mmHg	24-hour mean systolic blood pressure <135 mmHg	24-hour mean systolic blood pressure <130 mmHg	24-hour mean systolic blood pressure <120 mmHg	24-hour mean diastolic blood pressure <90 mmHg	24-hour mean diastolic blood pressure <85 mmHg	24-hour mean diastolic blood pressure <80 mmHg	24-hour mean blood pressure <140/90 mmHg	24-hour mean blood pressure <135/95 mmHg	24-hour mean blood pressure <135/80 mmHg	24-hour mean blood pressure <130/80 mmHg	24-hour mean blood pressure <125/75 mmHg	24-hour mean blood pressure <120/80 mmHg	24-hour mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	95.6	90.4	79.9	47.2	98.7	96.1	84.7	94.3	89.1	80.3	73.4	52.4	45.9	27.5

Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Intervention	Percentage of participants (Number)
	24-hour mean systolic blood pressure <140 mmHg	24-hour mean systolic blood pressure <135 mmHg	24-hour mean systolic blood pressure <130 mmHg	24-hour mean systolic blood pressure <120 mmHg	24-hour mean diastolic blood pressure <90 mmHg	24-hour mean diastolic blood pressure <85 mmHg	24-hour mean diastolic blood pressure <80 mmHg	24-hour mean blood pressure <140/90 mmHg	24-hour mean blood pressure <135/95 mmHg	24-hour mean blood pressure <135/80 mmHg	24-hour mean blood pressure <130/80 mmHg	24-hour mean blood pressure <125/75 mmHg	24-hour mean blood pressure <120/80 mmHg	24-hour mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	99.5	97.5	94.5	70.4	100.0	97.5	93.0	99.5	96.0	92.5	90.5	75.4	70.4	55.3

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8AM - 4PM. (NCT00791258)
Timeframe: Baseline to 12 weeks

Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Intervention	Percentage of participants (Number)
	Daytime mean systolic blood pressure <140 mmHg	Daytime mean systolic blood pressure <135 mmHg	Daytime mean systolic blood pressure <130 mmHg	Daytime mean systolic blood pressure <120 mmHg	Daytime mean diastolic blood pressure <90 mmHg	Daytime mean diastolic blood pressure <85 mmHg	Daytime mean diastolic blood pressure <80 mmHg	Daytime mean blood pressure <140/90 mmHg	Daytime mean blood pressure <135/95 mmHg	Daytime mean blood pressure <135/80 mmHg	Daytime mean blood pressure <130/80 mmHg	Daytime mean blood pressure <125/75 mmHg	Daytime mean blood pressure <120/80 mmHg	Daytime mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	88.2	79.9	66.4	28.8	95.6	83.0	65.5	86.9	72.9	61.1	53.3	31.9	27.9	13.1

Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Intervention	Percentage of participants (Number)
	Daytime mean systolic blood pressure <140 mmHg	Daytime mean systolic blood pressure <135 mmHg	Daytime mean systolic blood pressure <130 mmHg	Daytime mean systolic blood pressure <120 mmHg	Daytime mean diastolic blood pressure <90 mmHg	Daytime mean diastolic blood pressure <85 mmHg	Daytime mean diastolic blood pressure <80 mmHg	Daytime mean blood pressure <140/90 mmHg	Daytime mean blood pressure <135/95 mmHg	Daytime mean blood pressure <135/80 mmHg	Daytime mean blood pressure <130/80 mmHg	Daytime mean blood pressure <125/75 mmHg	Daytime mean blood pressure <120/80 mmHg	Daytime mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	96.5	93.5	83.9	51.8	98.5	92.5	83.9	95.0	88.4	81.9	77.4	56.8	51.3	33.2

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10p.m. - 6 a.m. (NCT00791258)
Timeframe: Baseline to 12 weeks

Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Intervention	Percentage of participants (Number)
	Nighttime mean systolic blood pressure <140 mmHg	Nighttime mean systolic blood pressure <135 mmHg	Nighttime mean systolic blood pressure <130 mmHg	Nighttime mean systolic blood pressure <120 mmHg	Nighttime mean diastolic blood pressure <90 mmHg	Nighttime mean diastolic blood pressure <85 mmHg	Nighttime mean diastolic blood pressure <80 mmHg	Nighttime mean blood pressure <140/90 mmHg	Nighttime mean blood pressure <135/95 mmHg	Nighttime mean blood pressure <135/80 mmHg	Nighttime mean blood pressure <130/80 mmHg	Nighttime mean blood pressure <125/75 mmHg	Nighttime mean blood pressure <120/80 mmHg	Nighttime mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	97.8	94.3	92.6	74.7	99.6	98.3	94.8	97.4	93.4	90.8	89.1	77.7	74.2	62.0

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10 p.m. - 6 a.m. (NCT00791258)
Timeframe: Baseline to 20 weeks

Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

The Percentage of Subjects Who Achieve BP Goal (<140/90 mmHg for Non-diabetics or <130/80 mmHg for Diabetics) From Baseline to 12 and 20 Weeks

Time-to-event Analysis of Percentage of Patients With a Cardiovascular (CV) Mortality Event, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke

Intervention	Percentage of participants (Number)
	Nighttime mean systolic blood pressure <140 mmHg	Nighttime mean systolic blood pressure <135 mmHg	Nighttime mean systolic blood pressure <130 mmHg	Nighttime mean systolic blood pressure <120 mmHg	Nighttime mean diastolic blood pressure <90 mmHg	Nighttime mean diastolic blood pressure <85 mmHg	Nighttime mean diastolic blood pressure <80 mmHg	Nighttime mean blood pressure <140/90 mmHg	Nighttime mean blood pressure <135/95 mmHg	Nighttime mean blood pressure <135/80 mmHg	Nighttime mean blood pressure <130/80 mmHg	Nighttime mean blood pressure <125/75 mmHg	Nighttime mean blood pressure <120/80 mmHg	Nighttime mean blood pressure <120/70 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	99.5	99.5	97.5	86.4	99.5	98.5	96.0	99.0	98.5	96.0	95.0	88.9	85.9	78.9

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	88.5	75.2	62.0	33.6	94.7	83.2	61.1	86.7	55.8	49.6	29.2

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	93.8	87.6	79.7	47.8	98.2	89.4	77.0	92.9	74.3	69.9	43.4

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	73.5	59.0	47.9	18.8	86.3	72.7	48.7	68.4	40.2	34.2	16.2

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	89.7	83.8	69.2	41.0	91.5	85.5	69.2	85.5	64.1	59.8	36.8

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	92.8	82.5	78.3	51.2	94.6	86.8	71.7	88.6	67.5	65.1	48.2

Intervention	Percentage of participants (Number)
	Systolic blood pressure <140 mmHg	Systolic blood pressure <135 mmHg	Systolic blood pressure <130 mmHg	Systolic blood pressure <120 mmHg	Diastolic blood pressure <90 mmHg	Diastolic blood pressure <85 mmHg	Diastolic blood pressure <80 mmHg	Blood pressure <140/90 mmHg	Blood pressure <135/80 mmHg	Blood pressure <130/80 mmHg	Blood pressure <120/80 mmHg
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	92.8	82.5	78.3	51.2	94.6	86.8	71.7	88.6	67.5	65.1	48.2

CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])

Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity Event

Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG). (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]

Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity or Mortality Event

CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])

Intervention	Percentage of Participants (Number)
	4 weeks: <140/90 mm Hg, N=975	4 weeks: <135/80 mm Hg, N=975	4 weeks: <130/80 mm Hg, N=975	4 weeks: <120/80 mm Hg, N=975	8 weeks: <140/90 mm Hg, N=929	8 weeks: <135/80 mm Hg, N=929	8 weeks: <130/80 mm Hg, N=929	8 weeks: <120/80 mm Hg, N=929	12 weeks: <140/90 mm Hg, N=865	12 weeks: <135/80 mm Hg, N=865	12 weeks: <130/80 mm Hg, N=865	12 weeks: <120/80 mm Hg, N=865	16 weeks: <140/90mm Hg, N=797	16 weeks: <135/80mm Hg, N=797	16 weeks: <130/80mm Hg, N=797	16 weeks: <120/80mm Hg, N=797	20 weeks: <140/90 mm Hg, N=745	20 weeks: <135/80 mm Hg, N=745	20 weeks: <130/80 mm Hg, N=745	20 weeks: <120/80 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	49.1	23.0	17.3	7.8	52.4	29.8	24.8	11.2	68.1	40.0	34.3	17.6	77.8	51.3	46.2	28.7	81.3	55.6	50.1	28.2

Intervention	Percentage of participants (Number)
	4 weeks: <90 mm Hg, N=975	4weeks: <85 mm Hg, N=975	4 weeks: <80 mm Hg, N=975	8 weeks: <90 mm Hg, N=929	8 weeks: <85 mm Hg, N=929	8 weeks: <80 mm Hg, N=929	12 weeks: <90 mm Hg, N=865	12 weeks: <85 mm Hg, N=865	12 weeks: <80 mm Hg, N=865	16 weeks: <90 mm Hg, N=797	16 weeks: <85 mm Hg, N=797	16 weeks: <80 mm Hg, N=797	20 weeks: <90 mm Hg, N=745	20 weeks: <85 mm Hg, N=745	20 weeks: <80 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	71.3	55.2	34.2	75.1	57.1	40.2	84.3	68.7	49.5	90.2	76.9	59.6	89.7	79.5	62.0

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=975	4 weeks: >10 and ≤ 15 mm Hg, N=975	4 weeks: >15 and ≤ 20 mm Hg, N=975	4 weeks: >20 mm Hg, N=975	8 weeks: ≤ 10 mm Hg, N=929	8 weeks: >10 and ≤ 15 mm Hg, N=929	8 weeks: >15 and ≤ 20 mm Hg, N=929	8 weeks: >20 mm Hg, N=929	12 weeks: ≤ 10 mm Hg, N=865	12 weeks: >10 and ≤ 15 mm Hg, N=865	12 weeks: >15 and ≤ 20 mm Hg, N=865	12 weeks: >20 mm Hg, N=865	16 weeks: ≤ 10 mm Hg, N=797	16 weeks: >10 and ≤ 15 mm Hg, N=797	16 weeks: >15 and ≤ 20 mm Hg, N=797	16 weeks: >20 mm Hg, N=797	20 weeks: ≤ 10 mm Hg, N=745	20 weeks: >10 and ≤ 15 mm Hg, N=745	20 weeks: >15 and ≤ 20 mm Hg, N=745	20 weeks: >20 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	61.3	21.0	10.5	7.2	54.7	20.7	14.1	10.6	43.8	24.1	15.8	16.3	30.4	22.8	21.5	25.4	31.4	19.9	22.6	26.2

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=975	4 weeks: <135 mm Hg, N=975	4 weeks: <130 mm Hg, N=975	4 weeks: <120 mm Hg, N=975	8 weeks: <140 mm Hg, N=929	8 weeks: <135 mm Hg, N=929	8 weeks: <130 mm Hg, N=929	8 weeks: <120 mm Hg, N=929	12 weeks: <140 mm Hg, N=865	12 weeks: <135 mm Hg, N=865	12 weeks: <130 mm Hg, N=865	12 weeks: <120 mm Hg, N=865	16 weeks: <140 mm Hg, N=797	16 weeks: <135 mm Hg, N=797	16 weeks: <130 mm Hg, N=797	16 weeks: <120 mm Hg, N=797	20 weeks: <140 mm Hg, N=745	20 weeks: <135 mm Hg, N=745	20 weeks: <130 mm Hg, N=745	20 weeks: <120 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	54.2	39.8	25.3	8.9	57.2	45.9	35.0	12.9	72.6	59.0	45.3	19.4	80.9	70.3	58.9	30.9	84.3	75.2	64.2	31.5

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=975	4 weeks: >15 and ≤ 30 mm Hg, N=975	4 weeks: >30 and ≤ 45 mm Hg, N=975	4 weeks: >45 mm Hg, N=975	8 weeks: ≤ 15 mm Hg, N=929	8 weeks: >15 and ≤ 30 mm Hg, N=929	8 weeks: >30 and ≤ 45 mm Hg, N=929	8 weeks: >45 mm Hg, N=929	12 weeks: ≤ 15 mm Hg, N=865	12 weeks: >15 and ≤ 30 mm Hg, N=865	12 weeks: >30 and ≤ 45 mm Hg, N=865	12 weeks: >45 mm Hg, N=865	16 weeks: ≤ 15 mm Hg, N=797	16 weeks: >15 and ≤ 30 mm Hg, N=797	16 weeks: >30 and ≤ 45 mm Hg, N=797	16 weeks: >45 mm Hg, N=797	20 weeks: ≤ 15 mm Hg, N=745	20 weeks: >15 and ≤ 30 mm Hg, N=745	20 weeks: >30 and ≤ 45 mm Hg, N=745	20 weeks: >45 mm Hg, N=745
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	51.4	36.6	10.5	1.5	45.8	37.7	14.3	2.3	30.5	43.1	22.4	3.9	23.2	35.9	32.0	8.9	20.4	36.2	34.0	9.4

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=454	4 weeks: <85 mm Hg, N=454	4 weeks: <80 mm Hg, N=454	8 weeks: <90 mm Hg, N=457	8 weeks: <85 mm Hg, N=457	8 weeks: <80 mm Hg, N=457	12 weeks: <90 mm Hg, N=457	12 weeks: <85 mm Hg, N=457	12 weeks: <80 mm Hg, N=457	16 weeks: <90 mm Hg, N=457	16 weeks: <85 mm Hg, N=457	16 weeks: <80 mm Hg, N=457	20 weeks: <90 mm Hg, N=457	20 weeks: <85 mm Hg, N=457	20 weeks: <80 mm Hg, N=457
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	69.6	53.5	31.9	82.1	66.1	43.5	90.4	76.6	56.5	94.8	83.2	65.9	95.4	86.2	72.0

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=453	4 weeks: >10 and ≤ 15 mm Hg, N=453	4 weeks: >15 and ≤ 20 mm Hg, N=453	4 weeks: >20 mm Hg, N=453	8 weeks: ≤ 10 mm Hg, N=431	8 weeks: >10 and ≤ 15 mm Hg, N=431	8 weeks: >15 and ≤ 20 mm Hg, N=431	8 weeks: >20 mm Hg, N=431	12 weeks: ≤ 10 mm Hg, N=402	12 weeks: >10 and ≤15 mm Hg, N=402	12 weeks: >15 and ≤ 20 mm Hg, N=402	12 weeks: >20 mm Hg, N=402	16 weeks: ≤ 10 mm Hg, N=371	16 weeks: >10 and ≤ 15 mm Hg, N=371	16 weeks: >15 and ≤ 20 mm Hg, N=371	16 weeks: >20 mm Hg, N=371	20 weeks: ≤ 10 mm Hg, N=356	20 weeks: >10 and ≤ 15 mm Hg, N=356	20 weeks: >15 and ≤ 20 mm Hg, N=356	20 weeks: >20 mm Hg, N=356
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	62.7	22.3	8.6	6.4	56.6	19.7	15.3	8.4	44.3	22.1	17.4	16.2	32.4	24.0	21.0	22.6	33.2	19.4	22.5	25.0

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=454	4 weeks: <135 mm Hg, N=454	4 weeks: <130 mm Hg, N=454	4 weeks: <120 mm Hg, N=454	8 weeks: <140 mm Hg, N=457	8 weeks: <135 mm Hg, N=457	8 weeks: <130 mm Hg, N=457	8 weeks: <120 mm Hg, N=457	12 weeks: <140 mm Hg, N=457	12 weeks: <135 mm Hg, N=457	12 weeks: <130 mm Hg, N=457	12 weeks: <120 mm Hg, N=457	16 weeks: <140 mm Hg, N=457	16 weeks: <135 mm Hg, N=457	16 weeks: <130 mm Hg, N=457	16 weeks: <120 mm Hg, N=457	20 weeks: <140 mm Hg, N=457	20 weeks: <135 mm Hg, N=457	20 weeks: <130 mm Hg, N=457	20 weeks: <120 mm Hg, N=457
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	56.4	41.4	27.1	7.9	67.6	54.3	40.9	16.2	81.4	67.2	54.1	27.6	88.8	80.3	67.0	39.0	91.5	85.6	74.8	47.1

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=453	4 weeks: >15 and ≤ 30 mm Hg, N=453	4 weeks: >30 and ≤ 45 mm Hg, N=453	4 weeks: >45 mm Hg, N=453	8 weeks: ≤ 15 mm Hg, N=431	8 weeks: >15 and ≤ 30 mm Hg, N=431	8 weeks: >30 and ≤ 45 mm Hg, N=431	8 weeks: >45 mm Hg, N=431	12 weeks: ≤ 15 mm Hg, N=402	12 weeks: >15 and ≤ 30 mm Hg, N=402	12 weeks: >30 and ≤ 45 mm Hg, N=402	12 weeks: >45 mm Hg, N=402	16 weeks: ≤ 15 mm Hg, N=371	16 weeks: >15 and ≤ 30 mm Hg, N=371	16 weeks: >30 and ≤ 45 mm Hg, N=371	16 weeks: >45 mm Hg, N=371	20 weeks: ≤ 15 mm Hg, N=356	20 weeks: >15 and ≤ 30 mm Hg, N=356	20 weeks: >30 and ≤ 45 mm Hg, N=356	20 weeks: >45 mm Hg, N=356
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	49.5	38.4	11.5	0.7	48.0	35.5	14.4	2.1	30.4	43.8	22.6	3.2	24.0	37.7	29.1	9.2	19.7	36.5	36.0	7.9

Intervention	Percentage of Participants (Number)
	4 weeks: <90 mm Hg, N=190	4 weeks: <85 mm Hg, N=190	4 weeks: <80 mm Hg, N=190	8 weeks: <90 mm Hg, N=190	8 weeks: <85 mm Hg, N=190	8 weeks: <80 mm Hg, N=190	12 weeks: <90 mm Hg, N=190	12 weeks: <85 mm Hg, N=190	12 weeks: <80 mm Hg, N=190	16 weeks: <90 mm Hg, N=190	16 weeks: <85 mm Hg, N=190	16 weeks: <80 mm Hg, N=190	20 weeks: <90 mm Hg, N=190	20 weeks: <85 mm Hg, N=190	20 weeks: <80 mm Hg, N=190
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	75.8	64.2	39.0	85.8	72.6	51.1	94.2	83.2	63.7	97.9	89.0	70.5	99.0	90.5	76.8

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 10 mm Hg, N=189	4 weeks: >10 and ≤ 15 mm Hg, N=189	4 weeks: >15 and ≤ 20 mm Hg, N=189	4 weeks: >20 mm Hg, N=189	8 weeks: ≤ 10 mm Hg, N=181	8 weeks: >10 and ≤ 15 mm Hg, N=181	8 weeks: >15 and ≤ 20 mm Hg, N=181	8 weeks: >20 mm Hg, N=181	12 weeks: ≤ 10 mm Hg, N=170	12 weeks: >10 and ≤15 mm Hg, N=170	12 weeks: >15 and ≤ 20 mm Hg, N=170	12 weeks: >20 mm Hg, N=170	16 weeks: ≤ 10 mm Hg, N=156	16 weeks: >10 and ≤ 15 mm Hg, N=156	16 weeks: >15 and ≤ 20 mm Hg, N=156	16 weeks: >20 mm Hg, N=156	20 weeks: ≤ 10 mm Hg, N=150	20 weeks: >10 and ≤ 15 mm Hg, N=150	20 weeks: >15 and ≤ 20 mm Hg, N=150	20 weeks: >20 mm Hg, N=150
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	67.7	16.9	11.6	3.7	60.8	20.4	14.9	3.9	41.2	32.4	12.9	13.5	32.7	26.9	21.8	18.6	37.3	18.0	26.0	18.7

Intervention	Percentage of Participants (Number)
	4 weeks: <140 mm Hg, N=190	4 weeks: <135 mm Hg, N=190	4 weeks: <130 mm Hg, N=190	4 weeks: <120 mm Hg, N=190	8 weeks: <140 mm Hg, N=190	8 weeks: <135 mm Hg, N=190	8 weeks: <130 mm Hg, N=190	8 weeks: <120 mm Hg, N=190	12 weeks: <140 mm Hg, N=190	12 weeks: <135 mm Hg, N=190	12 weeks: <130 mm Hg, N=190	12 weeks: <120 mm Hg, N=190	16 weeks: <140 mm Hg, N=190	16 weeks: <135 mm Hg, N=190	16 weeks: <130 mm Hg, N=190	16 weeks: <120 mm Hg, N=190	20 weeks: <140 mm Hg, N=190	20 weeks: <135 mm Hg, N=190	20 weeks: <130 mm Hg, N=190	20 weeks: <120 mm Hg, N=190
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	54.7	41.1	26.3	10.0	69.0	56.3	42.6	15.8	81.6	69.5	57.9	30.0	87.9	79.0	69.0	39.5	91.1	84.2	75.3	48.4

Intervention	Percentage of Participants (Number)
	4 weeks: ≤ 15 mm Hg, N=189	4 weeks: >15 and ≤ 30 mm Hg, N=189	4 weeks: >30 and ≤ 45 mm Hg, N=189	4 weeks: >45 mm Hg, N=189	8 weeks: ≤ 15 mm Hg, N=181	8 weeks: >15 and ≤ 30 mm Hg, N=181	8 weeks: >30 and ≤ 45 mm Hg, N=181	8 weeks: >45 mm Hg, N=181	12 weeks: ≤ 15 mm Hg, N=170	12 weeks: >15 and ≤ 30 mm Hg, N=170	12 weeks: >30 and ≤ 45 mm Hg, N=170	12 weeks: >45 mm Hg, N=170	16 weeks: ≤ 15 mm Hg, N=156	16 weeks: >15 and ≤ 30 mm Hg, N=156	16 weeks: >30 and ≤ 45 mm Hg, N=156	16 weeks: >45 mm Hg, N=156	20 weeks: ≤ 15 mm Hg, N=150	20 weeks: >15 and ≤ 30 mm Hg, N=150	20 weeks: >30 and ≤ 45 mm Hg, N=150	20 weeks: >45 mm Hg, N=150
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	56.1	36.0	7.9	0.0	54.1	34.3	11.6	0.0	35.3	38.2	22.9	3.5	28.2	40.4	26.3	5.1	26.0	40.0	26.7	7.3

Intervention	Percentage of participants (Number)
	12 weeks	20 weeks
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	71.3	84.8

Article	Year
Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials. PloS one, 2013, Volume: 8, Issue:7 Topics: Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Fumarates; Humans; Hypertension; Obesit	2013
Adiponectin effects on the kidney. Best practice & research. Clinical endocrinology & metabolism, 2014, Volume: 28, Issue:1 Topics: Adiponectin; Albuminuria; Amlodipine; AMP-Activated Protein Kinases; Animals; Benzimidazoles; Benzoa	2014
Telmisartan plus amlodipine single-pill combination for the management of hypertensive patients with a metabolic risk profile (added-risk patients). Current medical research and opinion, 2013, Volume: 29, Issue:1 Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzo	2013
Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials. Hypertension research : official journal of the Japanese Society of Hypertension, 2013, Volume: 36, Issue:4 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Calc	2013

Article	Year
Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension. Journal of the American Society of Hypertension : JASH, 2017, Volume: 11, Issue:8 Topics: Adipose Tissue; Adult; Amides; Amlodipine; Angiotensin II; Antihypertensive Agents; Blood Glucose; D	2017
The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients. Scientific reports, 2018, 03-02, Volume: 8, Issue:1 Topics: Adipose Tissue; Adult; Aminobutyrates; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compou	2018
Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis. Journal of clinical hypertension (Greenwich, Conn.), 2013, Volume: 15, Issue:8 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Body Mass Index; Double-Blind Meth	2013
Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. Journal of hypertension, 2014, Volume: 32, Issue:7 Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agen	2014
Efficacy and tolerability of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: a subgroup analysis of patients stratified by hypertension severity, age, sex, and obesity. Journal of clinical hypertension (Greenwich, Conn.), 2014, Volume: 16, Issue:10 Topics: Adult; Age Factors; Aged; Amlodipine; Blood Pressure; Body Mass Index; Dose-Response Relationship, D	2014
The Effects of Valsartan and Amlodipine on the Levels of Irisin, Adropin, and Perilipin. Clinical laboratory, 2015, Volume: 61, Issue:12 Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Proteins; Calcium; Carrier Proteins; Female; Fibro	2015
Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients. Internal medicine (Tokyo, Japan), 2008, Volume: 47, Issue:21 Topics: Adult; Aged; Amlodipine; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Hypertension	2008
Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. Journal of human hypertension, 2010, Volume: 24, Issue:11 Topics: Age Factors; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Bla	2010
Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives. Journal of hypertension, 2010, Volume: 28, Issue:8 Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Mass	2010
Blood pressure-lowering response to amlodipine as a determinant of the antioxidative activity of small, dense HDL3. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2011, Oct-01, Volume: 11, Issue:5 Topics: Aged; Amlodipine; Antihypertensive Agents; Antioxidants; Blood Pressure; Body Mass Index; Calcium Ch	2011
Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients. Journal of clinical hypertension (Greenwich, Conn.), 2011, Volume: 13, Issue:10 Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Co	2011
Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. Journal of hypertension, 2012, Volume: 30, Issue:3 Topics: Adipose Tissue; Adult; Amides; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Extrac	2012
Efficacy of amlodipine/olmesartan medoxomil ± HCTZ in obese patients uncontrolled on antihypertensive monotherapy. Current medical research and opinion, 2012, Volume: 28, Issue:11 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hydroch	2012
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet (London, England), 2013, Feb-16, Volume: 381, Issue:9866 Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Body Mass Index; Body Size; Body Weight; Ca	2013
Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. Internal medicine (Tokyo, Japan), 2004, Volume: 43, Issue:7 Topics: Aged; Amlodipine; Analysis of Variance; Body Mass Index; Calcium Channel Blockers; Dehydroepiandrost	2004
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clinical therapeutics, 2005, Volume: 27, Issue:5 Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; D	2005
Selective imidazoline agonist moxonidine in obese hypertensive patients. International journal of clinical practice, 2006, Volume: 60, Issue:5 Topics: Adult; Amlodipine; Anthropometry; Antihypertensive Agents; Female; Hemodynamics; Humans; Hypertensio	2006
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. European journal of clinical pharmacology, 2006, Volume: 62, Issue:10 Topics: Adult; Aged; Amlodipine; Atorvastatin; Biomarkers; Blood Glucose; Body Mass Index; Calcium Channel B	2006
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension (Dallas, Tex. : 1979), 2007, Volume: 49, Issue:5 Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds;	2007
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension (Dallas, Tex. : 1979), 2007, Volume: 49, Issue:5 Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds;	2007
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension (Dallas, Tex. : 1979), 2007, Volume: 49, Issue:5 Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds;	2007
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension (Dallas, Tex. : 1979), 2007, Volume: 49, Issue:5 Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds;	2007
Blood pressure and cardiorenal responses to antihypertensive therapy in obese women. Arquivos brasileiros de endocrinologia e metabologia, 2008, Volume: 52, Issue:1 Topics: Adult; Amlodipine; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Blood Pressure Mon	2008
The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men. The Journal of clinical endocrinology and metabolism, 1993, Volume: 76, Issue:6 Topics: Adult; Amlodipine; Androgens; Androstenedione; Calcium Channel Blockers; Dehydroepiandrosterone; Deh	1993

Article	Year
Benefits of Valsartan and Amlodipine in Lipolysis through PU.1 Inhibition in Fructose-Induced Adiposity. Nutrients, 2022, Sep-12, Volume: 14, Issue:18 Topics: Activating Transcription Factor 3; Adiposity; Amlodipine; Angiotensin Receptor Antagonists; Antihype	2022
Chronic blockade of angiotensin AT₁ receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats. British journal of pharmacology, 2014, Volume: 171, Issue:3 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Obesity Agents; Antihypertensive	2014
Ramipril/amlodipine single pill - effectiveness, tolerance and patient satisfaction with antihypertensive therapy in relation to nutritional status. Pharmacological reports : PR, 2014, Volume: 66, Issue:6 Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Humans; Hypertension; Medica	2014
Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations. Polskie Archiwum Medycyny Wewnetrznej, 2016, Apr-29, Volume: 126, Issue:4 Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers;	2016
Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. Hypertension research : official journal of the Japanese Society of Hypertension, 2010, Volume: 33, Issue:6 Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles;	2010
Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity. Journal of clinical hypertension (Greenwich, Conn.), 2011, Volume: 13, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv	2011
Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice. PloS one, 2012, Volume: 7, Issue:11 Topics: Adiposity; Amlodipine; Animals; Body Weight; Calcium Channel Blockers; Calcium Channels, L-Type; Cal	2012
Effect of amlodipine on insulin resistance & tumor necrosis factor-alpha levels in hypertensive obese type 2 diabetic patients. The Indian journal of medical research, 2004, Volume: 120, Issue:5 Topics: Adolescent; Adult; Aged; Amlodipine; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Female; Ho	2004
Adult hypertension: reducing cardiovascular morbidity and mortality. Prescrire international, 2005, Volume: 14, Issue:75 Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alcohol Drinking	2005
Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. American journal of hypertension, 2007, Volume: 20, Issue:4 Topics: Adipocytes; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates;	2007
[Overweight and obesity in hypertensive Spanish patients. The CORONARIA study]. Medicina clinica, 2007, Nov-10, Volume: 129, Issue:17 Topics: Amlodipine; Analysis of Variance; Antihypertensive Agents; Body Mass Index; Calcium Channel Blockers	2007
Peroxynitrite is Involved in the dysfunction of vasorelaxation in SHR/NDmcr-cp rats, spontaneously hypertensive obese rats. Journal of cardiovascular pharmacology, 2007, Volume: 50, Issue:6 Topics: Acetylcholine; Amlodipine; Animals; Aorta, Thoracic; Blood Glucose; Blood Pressure; Blotting, Wester	2007
ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring, Md.), 2008, Volume: 16, Issue:4 Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I	2008
[The effect on left ventricular mass of treatment with amlodipine and diet therapy in obese patients with arterial hypertension]. Minerva cardioangiologica, 1994, Volume: 42, Issue:6 Topics: Amlodipine; Combined Modality Therapy; Diet, Reducing; Evaluation Studies as Topic; Female; Heart Ve	1994
Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. European journal of clinical pharmacology, 1993, Volume: 44, Issue:5 Topics: Amlodipine; Blood Pressure; Female; Humans; Hypertension; Insulin; Insulin Resistance; Male; Middle	1993
Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2001, Volume: 33, Issue:3 Topics: Adult; Aged; Amlodipine; Calcium Channel Blockers; Dehydroepiandrosterone; Dehydroepiandrosterone Su	2001
Weight reduction and pharmacologic treatment in obese hypertensives. American journal of hypertension, 2001, Volume: 14, Issue:6 Pt 1 Topics: Adult; Amlodipine; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; C	2001

amlodipine and Obesity

Research Excerpts

Research

Studies (42)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

Change From Baseline in Postprandial Glucose

Change From Baseline in Postprandial Insulin

Change From Baseline in Postprandial Non-esterified Fatty Acids

Change in Mean Sitting Diastolic Blood Pressure (MSDBP)

Change in Mean Sitting Systolic Blood Pressure (MSSBP)

Number of Patients Achieving Blood Pressure (BP) Control by Visit (< 140/90 mm Hg)

Number of Patients Achieving Blood Pressure (BP)Control by Visit (< 130/80 mm Hg)

The Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (<140 mm Hg for Non-diabetics and <130 mm Hg for Diabetics) From Baseline to 12 Weeks

The Percentage of Subjects Achieving Seated Diastolic BP Goal (<90 mmHg for Non-diabetics or < 80 mmHg for Subjects With Diabetes) From Baseline to 12 Weeks

Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values

Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values

Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks

Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

The Percentage of Subjects Who Achieve BP Goal (<140/90 mmHg for Non-diabetics or <130/80 mmHg for Diabetics) From Baseline to 12 and 20 Weeks

Time-to-event Analysis of Percentage of Patients With a Cardiovascular (CV) Mortality Event, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke

Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity Event

Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity or Mortality Event

Reviews

Trials

Other Studies